FDA: More Data on Remestemcel-L for Graft Versus Host Disease Needed
In the CRL, the FDA recommended that the Company conduct at least 1 additional randomized, clinical study.
In the CRL, the FDA recommended that the Company conduct at least 1 additional randomized, clinical study.